← 홈

고형암 (전체)

791개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 791개
AntibodySHOTFDACuratedFDABiologicMerckvedotin plus pembrolizumab …Approved

pembrolizumab (Keytruda)

Multiple solid tumors · PD-1

#PD-1#Antibody#Approved#FDA승인#바이오정보모아추천+5
효능 ORR 100%임상시험 1620상태 APPROVED
ADCSFDAFDABiologicAstellasvedotin plus pembrolizumab …Approved

enfortumab vedotin (Padcev)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · Renal Pelvis and Ureter Urothelial Carci

#RenalPelvisandUreterUrothelialCa#ADC#Approved#FDA승인#인기+5
효능 ORR 44%임상시험 84상태 RECRUITING
ADCAFDAFDABiologicstaleAbbViePhase 3

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Advanced Solid Tumors Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase3#FDA승인#항체약물접합체+3
효능 ORR 33.3%임상시험 12상태 RECRUITING
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 655상태 RECRUITING
AntibodyAHotBristol Myers SquibbdeliveryPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 75%임상시험 431상태 ACTIVE
AntibodyAHotAstraZenecaderuxtecan 3Phase 3

Tremelimumab (Tremelimumab)

Hepatocellular Carcinoma · Muscle Invasive Bladder Cancer

#MuscleInvasiveBladderCancer#Antibody#Phase3#인기#항체+5
효능 ORR 84.6%임상시험 191상태 RECRUITING
ADCBHotBiologicAstraZenecavedotin plus PD-1 blockade …Phase 3

GEM (Gemcitabine, Gemcitabine (GEM))

Extranodal NK/T-cell Lymphoma · Nasopharyngeal Carcinoma (NPC)

#NasopharyngealCarcinomaNPC#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 50%임상시험 190상태 RECRUITING
ADCBHotBiologicAcademic and Community Cancer R…Phase 3

Lenvatinib (Lenvatinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · Solid Tumor

#SolidTumor#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 70.3%임상시험 164상태 RECRUITING
ADCAHotBiologicMerck Sharp & Dohme LLCderuxtecan (T-DXd) plus 5-f…Phase 2

5-FU (5-fluorouracil, 5-fluorouracil (5-FU))

Gastroesophageal Junction; Gastroesophageal Adenocarcinoma · Colorectal Cancer

#ColorectalCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 72.7%임상시험 162상태 RECRUITING
ADCBHotBiologicGileadderuxtecan, sacituzumab gov…Phase 2

SG (Sacituzumab Govitecan, Sacituzumab Govitecan (SG))

Urothelial Carcinoma; Muscle-invasive Bladder Cancer · Urothelial Cancer

#UrothelialCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 44%임상시험 162상태 RECRUITING
ADCBHotBiologicKosei Hasegawa, MD, PhDatPhase 3

Olaparib (Olaparib)

Carcinoma, Ovarian Epithelial · Ovary Cancer

#OvaryCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 70.3%임상시험 159상태 DISCONTINUED
ADCBHotBiologicAstellasvedotin plus pembrolizumab …Phase 3

EV (enfortumab vedotin, enfortumab vedotin (EV))

Urothelial Carcinoma (UC); Peripheral Nerve Disease · Carcinoma, Transitional Cell

#CarcinomaTransitionalCell#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 44%임상시험 146상태 RECRUITING
ADCAHotBiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Colorectal Cancer; Resectable Colorectal Carcinoma · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5
효능 ORR 71.7%임상시험 137상태 RECRUITING
ADCCHotBiologicSCRI Development Innovations, L…deruxtecanPhase 3

everolimus (everolimus)

Intracranial Meningioma · Renal Cell Carcinoma

#RenalCellCarcinoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 78.4%임상시험 136상태 DISCONTINUED
ADCBHotBiologicK-Group, Beta, Inc., a wholly o…atPhase 3

Gemcitabine Hydrochloride (Gemcitabine Hydrochloride)

Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 50%임상시험 135상태 RECRUITING
AntibodyAHotRochePhase 3

Obinutuzumab (Obinutuzumab)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · B-cell Lymphoma

#B-cellLymphoma#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 134상태 RECRUITING
ADCSHotBiologicNovartis PharmaceuticalsApproved

Prednisolone (Prednisolone)

Healthy · Solid Tumor

#SolidTumor#ADC#Approved#인기#항체약물접합체+3
효능 ORR 85.5%임상시험 132상태 RECRUITING
ADCBHotBiologicPharmacyclics LLC.Phase 3

Ibrutinib (Ibrutinib)

Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 93.9%임상시험 126상태 ACTIVE
AntibodyCHotBeiGeneVedotin, Tislelizumab, and …Phase 2

Tislelizumab (Tislelizumab)

Locally Recurrent Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 37.1%임상시험 125상태 RECRUITING
AntibodyBHotInnoventvedotin (an HER2-targeted a…Phase 3

Sintilimab (Sintilimab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 4.5%임상시험 123상태 RECRUITING

1 / 40 페이지

← 이전다음 →